Kuznicki Law is investigating the proposed sale of Landos Biopharma, Inc. (NasdaqCM: LABP) to AbbVie Inc. (NYSE: ABBV). Under the terms of the proposed transaction, shareholders of Landos will receive $20.42 in cash, plus one non-tradable contingent value right (with a value of up to $11.14 per share, subject to the achievement of a clinical development milestone) for each share of Landos that they own. Kuznicki Law is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Landos Biopharma, Inc. (NasdaqCM: LABP) Loss Submission Form
If you would like to discuss your legal rights regarding this case, you may, without obligation or cost to you, contact us toll free at (833) 835-1495 or fill out the loss submission form on this page.